Sign In
Buy DGX
$207.35
-0.0900 (-0.0434%)
At Close: Jul 13, 2026
Why Quest Diagnostics (DGX) is a Top Value Stock for the Long-Term
10:41am, Friday, 10'th Jul 2026
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Quest Diagnostics Now the Largest Clinical Reference Lab to Extend Oncology Test Access Through OncoEMR MPI
08:52am, Wednesday, 08'th Jul 2026
American Oncology Network (AON) and other community oncology providers launching now as part of a pilot program that provides access to Haystack MRD SECAUCUS, N.J., July 8, 2026 /PRNewswire/ -- Quest
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
10:51am, Monday, 06'th Jul 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics Incorporated (DGX) Hits Fresh High: Is There Still Room to Run?
10:16am, Thursday, 02'nd Jul 2026
Quest Diagnostics (DGX) is at a 52-week high, but can investors hope for more gains in the future? We take a look at the company's fundamentals for clues.
DGX's Stock Rises on Haystack MRD Test's Approval From NYSDOH
11:31am, Thursday, 25'th Jun 2026
Quest Diagnostics gains NYSDOH approval for Haystack MRD, expanding the cancer test to all 50 states and strengthening its oncology reach.
Quest Diagnostics Inc (DGX) Stock Up 3.0% but GF Value Says Overvalued -- GF Score: 83/100
06:12pm, Wednesday, 24'th Jun 2026
On June 24, 2026, Quest Diagnostics Inc (DGX) shares rose 3.0% today, currently trading at $203.11. This performance places the stock well within its 52-week ra
Quest Diagnostics Receives New York State Approval for Haystack MRD®, Broadening Patient Access to ctDNA Minimal Residual Disease Testing
08:52am, Wednesday, 24'th Jun 2026
Achieving the rigorous laboratory standard broadens access for providers and patients in New York; applies to use of Haystack MRD for patients with solid tumor cancers SECAUCUS, N.J., June 24, 2026 /P
Is it Apt to Hold Quest Diagnostics Stock in Your Portfolio Now?
10:01am, Tuesday, 23'rd Jun 2026
DGX gains from Advanced Diagnostics, physician and consumer testing growth, plus AI-driven efficiency efforts, even as debt and policy risks linger.
Here's Why Quest Diagnostics (DGX) is a Strong Momentum Stock
10:51am, Friday, 19'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Quest Diagnostics (DGX) is a Top-Ranked Value Stock: Should You Buy?
10:41am, Thursday, 18'th Jun 2026
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
UTI-causing Bacteria Resistant to Current Drugs, Finds National Study by Hackensack Meridian CDI and Quest Diagnostics
08:57am, Thursday, 18'th Jun 2026
Published in Nature Communications, the new study finds that nearly 70% of a common bacterial strain that causes urinary tract infections, pneumonia and wound infections was non-susceptible to the thr
Quest Diagnostics to Release Second Quarter Financial Results on July 23, 2026
09:00am, Wednesday, 17'th Jun 2026
SECAUCUS, N.J., June 17, 2026 /PRNewswire/ -- Quest Diagnostics Incorporated (NYSE: DGX), a leader in diagnostic information services, announced today that it will report its second quarter 2026 finan
SECAUCUS, N.J., June 16, 2026 /PRNewswire/ -- Quest Diagnostics (NYSE: DGX), a leader in diagnostic information services, today unveiled its 2025 Corporate Responsibility Report.
4 Outpatient Home Health Stocks Benefiting From Industry Trends
11:41am, Tuesday, 09'th Jun 2026
An aging population and rising telehealth and AI adoption boost demand in the Zacks Medical - Outpatient and Home Healthcare industry. DGX, DVA, LFST and AVAH stand to benefit.
Skip the Oura Ring IPO. Buy These 10 Stocks Instead.
12:00am, Friday, 05'th Jun 2026
Oura Ring's IPO looks like Peloton in 2020 - great product, dangerous price. Ten public wellness stocks own the real trade.
